×
Suggest this Article to:
TOP INDEXERS
Public Article
-
verified
UNFAVORABLE EFFECTS OF PEG- IFN (INTERPHERON) ALPHA+ RIBAVIRINB DEVELOPED IN 24 WEEKS OF TREATMENT BESIDE HEPATITIS C
ISSN: 2582 - 9130
Publisher: author
UNFAVORABLE EFFECTS OF PEG- IFN (INTERPHERON) ALPHA+ RIBAVIRINB DEVELOPED IN 24 WEEKS OF TREATMENT BESIDE HEPATITIS C
Indexed in
Chemistry Sciences
ARTICLE-FACTOR
1.3
Article Basics Score: 3
Article Transparency Score: 2
Article Operation Score: 3
Article Articles Score: 2
Article Accessibility Score: 3
SUBMIT PAPER ASK QUESTION
International Category Code (ICC):
ICC-0602
Publisher: Krishma Publication
International Journal Address (IAA):
IAA.ZONE/2582382389130
eISSN
:
2582 - 9130
VALID
ISSN Validator
Abstract
Almost 5.3% people are being ill with (hepatitis C virus HCV) in Pakistan. The therapy allotted to most of genotypes is a mixture of interferon and ribavirin. The patients received some side effects. The study was consisted of 25 people. Peg-Interferon alpha+ Ribavirinb treatment was prescribed for constant hepatitis C from September 2015 to February 2016 for 24 weeks. Those patients noted down in our questionnaire and updated us about side effects which they had faced during the whole period. Overall, side effects were fatigue, nausea, anemia, rashes, decreased appetite, chills, influenza like symptoms, neutropenia and hair loss. Most common side effect was hair loss (87%). It is concluded that combined therapy of peg-Interferon alpha+ Ribavirinb also have side effects. Further approaches with fewer side effects are needed for the treatment of hepatitis C. Key words: Hepatitis C virus HCV, treatment, Peg-Interferon, Side effects, Sus...
